Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Comparison with companies in other sectors?

Genomma Lab Internacional, S.A.B. de C.V. has a share price of 1.00B. You can analyze Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) competitors across different market sectors through stock heatmaps.

What are GNMLF's NET and operating margins?

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) operating margin is around 0.23, and net profit margin is approximately 0.07 as of the latest reports.

In what way does GNMLF's earnings per share (EPS) trend reflect its financial momentum?

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) EPS is 0.10 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Genomma Lab Internacional, S.A.B. de C.V. is 10.90, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Genomma Lab Internacional, S.A.B. de C.V.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Genomma Lab Internacional, S.A.B. de C.V. like P/E which is 18.93, P/B which is 1.77, and PEG which is 0.01. Compare them with sector averages to evaluate if the stock is priced fairly.

Genomma Lab Internacional, S.A.B. de C.V.

GNMLF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$1.09

$0.00(0.00%)

Fundamental Analysis of Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.10

P/E Ratio

10.90

ROE

0.12%

Net Margin

0.07%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.09B

Shares OutstandingTotal number of shares issued

$1.00B

Book Value/ShareNet worth per share

$11.41

Revenue/ShareAnnual revenue per share

$14.81

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.1

Net MarginNet income as percentage of revenue

7.21%

Operating MarginOperating income as percentage of revenue

22.64%

ROEReturn on shareholders' equity

12.09%

ROAReturn on total assets

4.32%

ROCEReturn on capital employed

20.81%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$2.38

Cash/ShareCash and equivalents per share

$2.22

FCF YieldFree cash flow as percentage of market cap

11.48%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$4.28

Dividend YieldAnnual dividend as percentage of stock price

21.18%

Financial Ratios Analysis data is not available for GNMLFFinancial Ratios Analysis details for GNMLF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for GNMLFSector Benchmarking details for GNMLF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Genomma Lab Internacional, S.A.B. de C.V. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Genomma Lab Internacional, S.A.B. de C.V.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Genomma Lab Internacional, S.A.B. de C.V.'s unique business strengths and challenges.

Key Financial Metrics for Genomma Lab Internacional, S.A.B. de C.V.

For Genomma Lab Internacional, S.A.B. de C.V., essential financial indicators include EPS 0.10, PE 10.90, and ROE 0.12. These key ratios reveal insights into Genomma Lab Internacional, S.A.B. de C.V.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Genomma Lab Internacional, S.A.B. de C.V. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Genomma Lab Internacional, S.A.B. de C.V.

Metrics like Net Margin 7.21% and ROA 4.32% shed light on how well Genomma Lab Internacional, S.A.B. de C.V. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Genomma Lab Internacional, S.A.B. de C.V. can sustain its operations and continue growing in the future.

Valuation and Market Position of Genomma Lab Internacional, S.A.B. de C.V.

Using ratios such as P/B Ratio 1.77 and PEG Ratio 0.01, investors can assess whether Genomma Lab Internacional, S.A.B. de C.V. is appropriately valued based on its financials and growth potential. These figures, combined with Genomma Lab Internacional, S.A.B. de C.V.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Genomma Lab Internacional, S.A.B. de C.V.

Financial health indicators, such as Debt/Equity Ratio 0.63 and Cash Flow $2.38, provide a snapshot of Genomma Lab Internacional, S.A.B. de C.V.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Genomma Lab Internacional, S.A.B. de C.V., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Genomma Lab Internacional, S.A.B. de C.V.

Investing in Genomma Lab Internacional, S.A.B. de C.V. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Genomma Lab Internacional, S.A.B. de C.V. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;